水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效

Clinical efficacy of silybin combined with entecavir for treatment of patients with post-hepatitis cirrhosis

目的:探讨水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效.方法:选取2014-01/2015-12武警浙江省总队医院嘉兴分院接受治疗的乙型肝炎肝硬化患者100例,采用随机数表法将100例患者分为实验组和对照组,各50例.给予实验组患者恩替卡韦联合水飞蓟宾治疗,给予对照组患者恩替卡韦治疗.结果:治疗前两组患者的肝功能指标无差异(P>0.05),治疗后两组患者的肝功能指标较治疗前均显著改善(P<0.05).实验组患者的肝功能情况显示优于对照组患者的肝功能情况(P<0.05).治疗前两组患者的肝纤维化指标无差异(P>0.05),治疗后两组患者的肝纤维化指标较治疗前均显著改善(P<0.05).实验组患者的肝纤维化指标情况显示优于对照组患者的肝纤维化指标情况(P<0.05).实验组患者有2例出现口苦、头晕、疲乏、腹部不适等症状,对照组患者有1例出现口苦、腹部不适的症状.两组患者均没有出现过敏等不良反应.结论:恩替卡韦联合水飞蓟宾治疗乙型肝炎肝硬化能够显著改善患者的肝功能、改善患者肝纤维化指标的情况,可以在临床上进一步推广和使用.

AIM：To evaluate the effi cacy of silybin combinedwith entecavir in the treatment of patients with post-hepatitis cirrhosis.METHODS：One hundred patients with posthepatitis cirrhosis treated from January 2014 to December 2015 at Zhengjiang Armed Police Hospital Jiaxing Branch were selected and randomly divided into an experimental group and a control group,with 50 cases in each group.The experimental group was given silybin with entecavir,while the control group was given entecavir alone.RESULTS：Before treatment,there was no difference in the indicators of liver function between the two groups（P 〈0.05）.After treatment,liver function of both groups was significantly improved（P 〈0.05）,and the improvement was significantly better in the experimental group than in the control group（P 〈0.05）.Before treatment,there was no difference in indicators of hepatic fibrosis between the two groups（P 〈0.05）.After treatment,hepatic fibrosis of both groups was improved signifi cantly（P 〈0.05） and the improvement was significantly better in the experimental group than in the control group（P 〈0.05）.Two patients in the experiment group had bitter taste,dizziness,fatigue,abdominal discomfort and other symptoms,while one patient in the control group had bitter taste and abdominal discomfort symptoms.No serious adverse reactions including allergy occurred in either group.CONCLUSION：Silybin with entecavir can significantly improve liver function and liver fibrosis in patients with post-hepatitis cirrhosis.